Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Dyadic reported Q2 revenue of $961,138, a 0.6% decrease year-over-year, while net loss widened to $2.12 million driven by higher G&A and cost of revenue. The company noted commercialization progress including product shipments to IBT Bioservices and initial sales of recombinant proteins for cultivated-meat applications, alongside continued grant funding from the Gates Foundation and CEPI.
Key figures
- Revenue
- 961138
- Revenue Yoy
- -0.6%
- Net loss
- 2123884
- Cash position
- 4794798
- Grant revenue
- 837252
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.